-transparent.png){kind=logo}
Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. 2010
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
Department of Technology and Product Development, CK Life Sciences Int'l., (Holdings) Inc., 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong SAR, China. tak.chan@ck-lifesciences.com
Cucurbitacin B is an anti-cancer drug candidate and its efficacy has been demonstrated in hepatocellular carcinoma (HCC). To explore its mechanism against HCC, BEL-7402 cells were treated with cucurbitacin B in vitro. Treatment with cucurbitacin B induced S phase arrest and apoptosis. The growth inhibition effect was associated with cyclin D1 and cdc-2 down regulations. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibited c-Raf activation without affecting STAT3 phosphorylation. Moreover, in vivo study demonstrated that cucurbitacin B is effective against BEL-7402 xenograft when administrated orally.
Related Publications
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
January 2008,
The American journal of Chinese medicine,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
December 2015,
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
October 2015,
Toxicology in vitro : an international journal published in association with BIBRA,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
January 2015,
The American journal of Chinese medicine,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
December 2004,
Acta pharmacologica Sinica,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
March 2015,
Cell biochemistry and biophysics,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
November 2007,
Biochemical and biophysical research communications,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
September 2006,
Onkologie,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
August 2010,
Free radical research,
Kin Tak Chan, and
Fan Yan Meng, and
Qian Li, and
Cheong Yip Ho, and
Tsz Shan Lam, and
Yu To, and
Wai Him Lee, and
Miao Li, and
Kee Hung Chu, and
Melvin Toh
December 2015,
Acta pharmacologica Sinica,
